AtaiBeckley Inc. (ATAI) · Aug 31, 2026 · Acquisition

AtaiBeckley clears U.S. antitrust review, but Lilly deal still awaits Australia

Antitrust review advanced — U.S. waiting period expired; Australian waiting period ends September 10

The Eli Lilly acquisition clears its U.S. antitrust hurdle, while Australian approval remains subject to a September 10 waiting-period expiry.

The merger was already the market’s baseline, so this is a process update rather than a new deal thesis. AtaiBeckley had previously disclosed the July 15, 2026 merger agreement with Eli Lilly, making regulatory progress partly known rather than a fresh strategic surprise. (Merger Agreement) 〔0〕

The U.S. antitrust hurdle is now cleared. The Hart-Scott-Rodino waiting period expired on August 28, removing one closing condition and modestly reducing execution risk. (U.S. Antitrust Review) 〔1〕

Foreign review is also progressing, but the deal is not fully cleared. The U.K. competition authority indicated it had no further questions at that time, while Australia determined the merger may proceed only after a 14-calendar-day waiting period. (Other Regulatory Reviews) 〔2〕

Net read: neutral on expectations, with lower—but not eliminated—closing risk. Nothing here changes the agreed economics or adds a competing bid; it confirms expected regulatory momentum while leaving the September 10 Australian waiting-period expiry and shareholder approval as remaining execution points. The filing therefore advances the transaction without creating a clean beat-versus-consensus signal.

What to watch next

Australian waiting period expires September 10

Original filing on SEC EDGAR

More AtaiBeckley Inc. news

AtaiBeckley clears U.S. antitrust review, but Lilly deal still awaits Australia | ATAI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.